Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study
Authors:
- 31 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 217 (6) , 861-868
Abstract
The low efficacy of rotavirus vaccines in clinical trials performed in low-resource settings may be partially explained by acquired immunity from natural exposure, especially in settings with high disease incidence. In a clinical trial of monovalent rotavirus vaccine in Bangladesh, we compared the original per-protocol efficacy estimate to efficacy derived from a recurrent events survival model in which children were considered naturally exposed and potentially immune after their first rotavirus diarrhea (RVD) episode. We then simulated trial cohorts to estimate the expected impact of prior exposure on efficacy estimates for varying rotavirus incidence rates and vaccine efficacies. Accounting for natural immunity increased the per-protocol vaccine efficacy estimate against severe RVD from 63.1% (95% confidence interval [CI], 33.0%-79.7%) to 70.2% (95% CI, 44.5%-84.0%) in the postvaccination period, and original year 2 efficacy was underestimated by 14%. The simulations demonstrated that this expected impact increases linearly with RVD incidence, will be greatest for vaccine efficacies near 50%, and can reach 20% in settings with high incidence and low efficacy. High rotavirus incidence leads to predictably lower vaccine efficacy estimates due to the acquisition of natural immunity in unvaccinated children, and this phenomenon should be considered when comparing efficacy estimates across settings. NCT01375647.Keywords
Funding Information
- Bill & Melinda Gates Foundation (OPP1017093)
- National Institutes of Health (AI114888)
This publication has 40 references indexed in Scilit:
- Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria ExposureNew England Journal of Medicine, 2013
- Protective Effect of Natural Rotavirus Infection in an Indian Birth CohortNew England Journal of Medicine, 2011
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- The effect of rotavirus vaccine on diarrhoea mortalityInternational Journal of Epidemiology, 2010
- Oral Rotavirus Vaccines: How Well Will They Work Where They Are Needed Most?The Journal of Infectious Diseases, 2009
- Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier EstimatorThe American Statistician, 2005
- Protective Immunity after Natural Rotavirus Infection: A Community Cohort Study of Newborn Children in Guinea‐Bissau, West AfricaThe Journal of Infectious Diseases, 2002
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982